DuoCort gains European OK for hydrocortisone replacement therapy
This article was originally published in Scrip
Executive Summary
The European Commission has granted marketing authorisation to Swedish drug maker DuoCort Pharma for its dual-release hydrocortisone replacement therapy Plenadren (hydrocortisone, modified-release) as a once-daily oral treatment for adults with adrenal insufficiency – the first new therapy for the condition in 50 years.